September 30, 2021 10:53 AM EDT

Otsuka puts nearly $1 billion on the line for four neuropsychiatric candidates from Sunovion

Nicole DeFeudis

Editor

It’s been six years since Otsuka got its Lundbeck-partnered antipsychotic Rexulti approved to treat schizophrenia in the US. Now, the company has its sights set …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Otsuka puts nearly $1 billion on the line for four neuropsychiatric candidates from Sunovion

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Ot­su­ka puts near­ly $1 bil­lion on the line for four neu­ropsy­chi­atric can­di­dates from Sunovion

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Otsuka puts nearly $1 billion on the line for four neuropsychiatric candidates from Sunovion

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial